-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Q5Xdu1q5Nfg22pcvL2zpfmyBlSmPhlEcDyFZ/65dSXFe7juRXL2UuzgklSqL+Lwj
 +FAIqCnojPMCfV71GqLfVw==

<SEC-DOCUMENT>0001129928-09-000061.txt : 20090901
<SEC-HEADER>0001129928-09-000061.hdr.sgml : 20090901
<ACCEPTANCE-DATETIME>20090901123052
ACCESSION NUMBER:		0001129928-09-000061
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090901
FILED AS OF DATE:		20090901
DATE AS OF CHANGE:		20090901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		091047961

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 5.1.2.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>&#160;</div>
<div>&#160;</div>
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1"></div>
<div>
<br>&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form 6-K</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report of Foreign Private Issuer</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of the Securities Exchange Act of 1934</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the month of&#160;September 2009</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number 000-31062</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation of registrant&#8217;s name into English)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210, 1167 Kensington Crescent NW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary, Alberta, Canada T2N 1X7</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div></div>
<div id="PN" style="PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2"></div></div>
<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div></div></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NUMBER</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div></td></tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News Release Dated&#160;September 1, 2009 -&#160;Oncolytics Biotech&#174; Inc. Announces Issuance of 32nd U.S. Patent</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div></td></tr><tr>
<td align="left" valign="center" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td align="left" valign="center" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="center" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;September 1, 2009</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;Doug Ball</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Doug Ball</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<br>
<br></body>
</html>







</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<html>
<head>
    <title>exhibit99.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 5.1.2.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="exhibit990.jpg" alt="">&#160;<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">210, 1167 Kensington Cr. N.W</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary, Alberta</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Canada T2N 1X7</font>
<br></div></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%"></div></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR IMMEDIATE RELEASE</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="left">
<br>&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#174;</font> Inc. Announces Issuance of 32<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> U.S. Patent</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB --- September 1, 2009</font> - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (&#8220;Oncolytics&#8221;) today announced that it has been granted its 32<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> U.S. Patent, No. 7,582,289, entitled &#8220;Viruses
for the Treatment of Cellular Proliferative Disorders.&#8221; The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;This U.S. patent expands our intellectual property portfolio regarding oncolytic viruses, in addition to reovirus, that can be modified to grow selectively in Ras-mediated cancers,&#8221; said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.&#160;&#160;&#160;&#8220;Including the patent issued today, Oncolytics
has now secured five U.S. patents covering the use of other oncolytic viruses to treat Ras-mediated cancers.&#160;&#160;Patents covering similar subject matter have been granted in other jurisdictions as well.&#8221;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. Patents issued previously include:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div></td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. Patent No. 6,596,268, which covers adenoviruses modified in the VAI gene;</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div></td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. Patent No. 7,344,711, which covers adenoviruses modified in the VAI and VAII genes;</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div></td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. Patent No. 6,649,157, which covers herpes simplex virus (HSV) mutated in the <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub; FONT-FAMILY: Times New Roman">&#947;1</font>34.5 gene; and</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div></td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. Patent No. 7,252,817, which covers modified HSV, where the <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub; FONT-FAMILY: Times New Roman">&#947;1</font>34.5 gene is lacking, inhibited or mutated such that PKR activation is not blocked.</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>,
its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.&#160;&#160;For further information about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company&#8217;s belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company&#8217;s
expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company&#8217;s business and technologies, involve known and unknown risks and uncertainties that could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials,
uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except
as required by applicable laws.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy Ward</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210, 1167 Kensington Cr NW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary, Alberta T2N 1X7</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel: 403.670.7377</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax: 403.283.0858</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></td>
<td align="left" valign="top" width="26%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Equicom Group</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick Hurst</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325, 300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave SW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary, Alberta T2P 3C4</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel: 403.538.4845</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax: 403.237.6916</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></td>
<td align="left" valign="top" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Investor Relations Group</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika Moran</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11 Stone St, 3rd Floor</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New York, NY&#160;&#160;10004</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
<br>
<br></body>
</html>







</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit990.jpg
<TEXT>
begin 644 exhibit990.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!X`````0```'@````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK-\7>+_#?@/P[>>+O&&N6NFZ7IUNT]]?WLPCB@C49+,QZ"
M@"^\R*,YS6-XS^)7@#X=:;_;'Q`\::3HEIN"BYU;48[>,DG`&Z0@<GBO@?XX
M_P#!4/X]?'_XF7'P%_8!\#273.[1Q^)A:B6XN%'WI8DD`CMXASB27)/!PO0U
M?`'_``1G^+/Q8U)/'7[7W[0M]+?7`,ES9:=,U[=*6W;E-S<$HI'R'Y49<Y'(
M`:O.EC959<N'@Y>>R-/9V^)V/JIO^"E'[#$;M&_[2/A_<K$'#2$?F$YK9\$_
MMT_L@_$?5#HG@W]H/PQ<W>Z-5@EU%8&=G;:JKYNW>Q)QA<FO)-/_`."+/[$M
MO8PV]WIOB:YE2)5DN7\12*TK`<L0@"@GK@`#G@5A_$7_`((@_LK>(-%^S^`/
M$?B3PY?IN,=VU]]MC)(P-\<HY`Y^ZRGGDT<^96^&/WL3]EW/LRTO[.^@6ZL[
ME)8F'R2QN&5OH1P:E#*W0YK\KO'/[.W[>?\`P3$U4?$;X,>/KCQ)X+MI`UXE
MHDCVR0K("%N[-B1&IW']Y$>-SG<F>?J_]AO_`(*:_"[]K".'P1XBMH?#?CAE
M=O[$>5FAO53&9+:0@;C@Y,1^==K'Y@-U72QU.53V=1.,NSZ^@2IM*ZU/J.BD
M1MRAL=12UW$!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`-D/R$?J:_,3]L3XT_$
M[_@I%^TC!^Q]^SL[P^&]!OIAJE])<XM[UX9%62]F"]88CQ&O)9F!QD@+]=_\
M%*OVA-2_9U_90UWQ-X<N1#K6L,FCZ-+E@T<T^0TBD#ADB65QD@90#.2!7`_\
M$<OV;K'X5?LTQ?%;4[/&M^.F%XTDL?S1V*EEMT'^RPS+GG=YB^@QYN+<L17C
MAUMO+T[&D?<7,>X_LM_LJ_"S]D[X>1^!/AII"B2;;+J^JS$M<:A<!0#([$DA
M<YVIG:HX'J?3Z`,#%%>A"$:<5&*LD9MMN["BBBJ`;,JNA1E!!&""*_/S_@I?
M_P`$[/#WA'PW+^U/^RYH$V@Z[H5VM_KFGZ&SQJ8EQFZMXXQ^ZEC;$C%2H*AF
M(R.?T%J"_L[:_MGL[R!)8949)8I4#*ZD8*D'@@C@@USXBA"O#EEOT?8J,G%W
M1\W?\$TOVTT_:U^#[6?BJ3'B[PPD5MX@+;0+T,I\N[0*!@/M;(P,.K`9&#7T
MQ7Y8>.O!\W_!-?\`X*;^'=7\%3/#X0\6W:-'91LK;;&[F$4]L4&WY8I</'TP
M!&,G#Y_4R)MV>.AK#`5ISA*G/XHNS'.*3NNH^BBBN\@****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`/SI_X+NZW=7=W\,/APT:+:W<U_=O<*#YBL#!#@<XQB4GIU`[<5]_
M>`_"NG>!O!VE^#=(`%KI>G06MN!&J_)'&J`X4`#(&>!BOS\_X+L:9J$'B?X5
M^,Y;?&FV_P#:%O-<[QA9#);2;<?>/RHQX';UP#^AWAW5[#7M#M-;TN;S;6\M
M8Y[:7:1OC=0RM@@$9!!P:\W#I/'UK^7W6-)?PXEVBBBO2,PHHHH`****`/@/
M_@O)X/T.7X4>!_'S6V-3MO$<NGQS*`,P2V[RLIXR</`A'/&6_O5]C?LWZYJW
MBGX!>"/%&O7AN+W4?"&FW-Y,4"^9*]LC,V%``R23P!7R-_P7CU33XO@3X)T6
M2\C%W-XN>XAMBXWO%':2H[@>BM+&">V\>M?6/[+D=Q9_LU_#ZRO+62&:'P3I
M22Q2H59&%I&""IY!&.AKSJ3MCZGHOU*_Y=1/*_\`@IY^T]\4OV4?@;I?Q"^$
MS::NHWGB>&PE.IV9G3RFM[B0X4,N#NC7G/K7FG[$/_!3OQ%X^\=#X%_M9V-A
MH7B74O*G\,ZM:Q^39:E%,JO#'RS`,ZL&C<,5D#`##8#6/^"Z#;OV4_#XZ?\`
M%=V_/_;I=UB^+_\`@GKX8_:X_8<^&'C+P@8-*\?:5\/-,_LS4C\B7R);(5MI
MR.V?NOU0G^Z2*RJO%?6W[-_"MNY7N\EF?3/[9?Q'^(OPA_9H\6_%#X77^G0:
MSH&F&]A?5+5IH6CC=6E4HI!+-'O"\X#$$UQ__!-']I'XE?M3?LZS?$_XK/I[
M:FGB.ZL5_LVT,,?E1I$5^4LW.7;G-?'VA_MW^/K[]EWXG?L6?M6V-[9^-=+\
M)7UKI&J:@");HQ1$_9K@GK*$&4ER1*N.2Q!?Z$_X(B#=^QG<<_\`,Z7_`/Z*
MMZ*6*]OC(J+=K.Z\[@X*$+-'UKKNO:/X6TJZUWQ!J4%G96=N\UW=W4PCCAC4
M99V9N%``Y)KXX'[??[1G[67C74/`7[`'PMTZ33-(N`NI>/?&#,+,X;A8XEY&
M]02N[+%23M7&3Z7_`,%4/"_COQ?^Q-XPTGP!')+<)';7&H6D%L99+BSCN$>5
M%503D!0^1CA#R*\K_P""(7CGX:2?LZZEX`TC68E\3P^(+F^UC3)KM#*\;+$D
M=Q'&/F$6U40DC'F*_/(K2O5D\6J*=DU?_AF))*-SO;KP-_P5BLO.U.U^.GPC
MNY!"/*T]_#EVD;,NX[0V<J6R%))(``P!@Y]M^!MS\=;SP:+S]H/2_#=CKLD[
MDV?A:6>2WAB'"@R3'+N<$G`4#('.,GL57<H;-*/D/UKKI45!WN_ON2W<X']I
M']HSX:_LP?#6[^)WQ.U<P6L'[NSM(2#/?W!&4@A4_><X^@&6)`!-?.GP@^/?
M_!1S]L#2(OBC\'/#'@3X=^#[F%AI;^*EGU"XOV#[2X\O9M3(;!*KG'&X$,>5
M_P""[G@GQ;J_PC\&>-=,GO)-(TG79H]5M8;=FBB::("*XD8<)M*M&,C!,W4'
M&?HK_@GMX\\&_$/]D#P)J?@FVMK:WLM`AT^ZLK=L_9;F!1'+&<@8.X%NF"'!
M!(()XW.=7'.E)M)*_K_PQ25H<QP7BJ'_`(*S>`=&D\66/B7X5^-'L\.WAJPT
M>ZM)KQ>A"2R2!01G=@D9VX!YJ_\`L6_\%*?AU^UCKLGPXU/PK>^&/&5I:R37
M&CW;B2&81D"3R9."2I/*,H8`$\@$CZ4D^7'N*_)W]EZ$>/?^"PE]K_PGO7M]
M,B\8:U?7%Q',9EFM%682_.B@;)7;*@C`$B+EN"9KU*F&J04)7YG;74<4I7/U
MF5@XR*^-_P!@+]MCXY?M'?M-?$3X4?$J?1VTCPPEVVEC3]-:&4&.^,"[VWL&
M^3V'/-?8\8^7=ZU^;G_!(?'_``W-\9^W[J__`/3L:WQ4YQQ%%)VNW?[B4ERL
M_26JFO6FIWVCW5KHNJ+8W<ENZVUXUN)1#(0=KE"0&P<'&1G&,BK3-M[4,-RE
M<UW$GP,/^"BO[3/[*W[3!^$'[=NA:2WAN^&-/\2>'M*DAC\LOA;M<N_F1]!)
M']^/DX./F^SO&'QG^&'@7X7W'QD\3^,["W\-06`O&U@7`>%X6&49"N?,+9`4
M+DL2`,FN>_:E_9:^&'[5GPRG^'/Q(L#E0TNDZM`@^T:;<[2!-$3^14_*PX/M
M^8O[.?[.OQ%^/O[1,O[`/Q%^,^H/X+^'NKZE>W-G;2MY<OV>=()!`&R4+LPQ
MNR(PTC*-S'/D5*E?"SY'[RE\/KYFEE)770^MOV7/VN?VN_VU_CAJ'B/X9:)I
M/A?X0:3?".2_U;26FO;T(>88W\P+YK]6P"L0(!+-C/TU\=-,^.NK^!OLW[/G
MB?0-(\0B\C87GB6QDN+7R.?,4I&0VX\8/08-;OP_^'W@_P"%OA"P\!^`M!M]
M,TC3+=8+*RM4VI&@_F2<DD\DDDDDUM5W4J,U2M.5V]_\D0VN:Z/C/]HGQO\`
M\%//V<O@YK?QI\3?%_X5W]CH4,<EQ9V'AB[$L@>:.(!=T@'5P>?2J/[+WQ3_
M`."FG[5?P>L?C1X2^*WPNTRQO[FYACM-2\,71E5H9GB8G9(1@E<CV/->K?\`
M!4W_`),/^(1_Z<;3_P!+K>L#_@CJN?V#_#?/_,5U3_TMEKCY9+&JGS.UK[E_
M9O8]A_9ZT3]I'1M!OQ^TMXW\,ZUJ<EV#8-X6TR6V@A@"#AO-)9G+9YZ8`]Z\
MW_X*9_M)_$[]E?\`9[M_B9\*&T]-3E\26UB6U.T,\?E/',S?*&7G*+SGUKZ)
M5=O>OCK_`(+A?\F=6/\`V.UE_P"B+FNG$2E2PLG%ZI$P^(]C_8-^-/CG]H3]
MEOPS\7OB/)9MK&J_:Q=FPMC#%^[NYHEVJ6;'RHO<\UT_[0W[0?PV_9G^&UY\
M4OBAK0M;*V&RWMX\-/>SD$I!"F?G=L?0`$D@`FO+?^"31S^P7X(/J=1_].%Q
M7C/_``79\*?$#5_A+X-\4:#9W$V@:/K-P=;\G<4AFDC1;>:0`$`#$R!B1AI%
M'\7&3K3IX%5=W8.7WK'0?#?]JG_@H+^V5)#XK_9L^$OAOP%X,61A'KOCGS;E
M]14LX#Q+&%#*-@!V@@%B`[8Q7=OHG_!5SPX?[6/C;X/>)A'Q_8S:;?60ER<;
MO.!.W;G.,<XQ77?\$]?$OPZ\2_L>^!/^%9WL<EE8>'K>TNX5FWO;W:(/M".-
MQ*MYN]MI.<,.@KVNKHTG4IJ3FW?L]`O9V,3P`OC?_A%+%_B1_9HUPVRMJ:Z.
M)!:K*>66+S"6*CID\G&<#.!\O_MO?\%)/$?[/'QMT3]G3X3_``VLM6\2:J+-
MI+[7;MXK*+[3*8XD'E_,Q)!+,2`HQPW./KNO*OVDOV/?@'^U5IL>F?%[P1'=
M75M$4L-9LY/(O;0$Y(CE7G&>=K;ESR5-:8B%:5&U*5F)-)W9YA<?#W_@JIKE
M]!K\G[0GPNT@PDR1Z+:>&[B:WE\SK%-(_P`[",9VLA7<1SP:Z3X+7_\`P46M
M_&=EH7QYT/X8S>'XYYO[0UW1+R[2[FC&[R_+@(VJ2=@^8GC/>O*)_P#@FK^U
M'\-+-[?]G'_@H%XKL+:(0O;Z5XB+S1ET(&#(KD)'L4`((B#C!X/'GUI_P4&_
M;0_98_:&T_\`9P_:=TKP]XV:ZO[6/[?H:!+MX+F5E21!$%3?EE/EO&IPO?<&
MKC]K[!IU%)7=M[HOEYMC]&`,#%%%%>L9GRM_P5U^`]U\9/V2K_7=)TTW.J^#
MKI=7MEB4%S;JI6Y4<'_EDS/@=?+`S6G_`,$I_C_9?'#]DK1+"\U4S:UX21=&
MUA)"3)B,?N)"2Q+;X=GS9Y97Z8P/I"_M+>^M)+2[A22*6,I)'(N5=3P01W!&
M17Y:^*+7XC_\$?OVO)/&&DZ6VJ_#;QE--Y&GV\Q'FV@<-Y)'W5N;??\`(3\K
M(Q&1N.WS,3_LN*CB/LO27EV9I'WHV/U0R#T-%<W\*OBIX$^,W@FQ^(/PX\0V
MNJ:3J$(>"YM9U?:?XHWVD[74\,IY!&#725Z,9*2NMC,****H`I&95ZFE)P"?
M05\K_P#!1G_@H3H'[*O@I_"'P]U/3=0\>Z@#%;V+3K(=)C9"?M4\8YQC&Q#C
M<2#RJFLJU:%&'-(:3D[(^8_VZ-=C_;B_X*-^%/V;_!R2W6E>'KM-+U.:&1FC
MSO$U])@,H`CC7RRP(8E"!GY<_I[I]I'8VR6D";8XD5(QG.%`P!GO7QE_P28_
M8MU3X3>&+C]I/XMVSGQAXOMB]G'="3SK&SE82,90X!$\K`.V>0,#/WA7VI7'
M@:=1J56IHY._RZ%U))NRZ'D'[97[(WAO]LOX<67PS\5>+=0T6VL=9CU&.ZTR
M.-I'=(I8PI\P$`8D)]>*[KX._#BR^#WPN\/?"O3=2FO+?P]HUMIT%U<`"25(
M8P@=@O`)`R<<5\K_`+=__!17XK_LR_MM_"#]D3X>>#M+N+?XF>&M=U2\UZZ\
M,:MK5Q9-IZQLJ1V.F9FE#[R"W1.IX!KK/^"?_P#P4,/[6GCGXC_!#Q]X<M-"
M\:_#;6([>[L?L]YI\^IV,J*\.H+IFH11WEI$P=%S(&1FSLD;!"]JI04^?J9F
M]^V/_P`$[?@S^V/=V/B'Q+=7>@Z]8;8QKVCQQ^=<6XSB&57!5P"<J2-R\@'!
M(KKOV._V5_#W['WPFD^$WACQ5?:Q;2:O/?\`VS48HTDW2*@*XC`&!L&._->J
MDX&:^</VG_VYM9^`_P"V[^SK^R'I7P_M=0A^-VI^(8M0UNXO61M+ATS3?M0\
MN,+AWD=XQDD`*K<$D8E8>BJOM$O>&VVK,^C3$K`JV"",$$5\Q_%3_@E9^S_X
MT\8M\3/ACK&O?#?Q([EWU+P5?_9D=F8%R8C\J[L'(0J#N)()KZ>KQG]O_P#;
M"L/V#?V4?%G[4>I_##6_%\/AFS63^Q-"`$DKNZQJTLC`K;VZE@TL[96)`S$-
MC%.K1IUE::N";6QR=K^PM\9UNXGO_P#@H1\69[=9%\^!;BT0R)D;EW"+*DC(
MSVSGM7J?P"^`.G?L_:!=^&='^)'B_P`0VEU<":,>+];_`+0DMVQAA'(R!PIX
M)4DC/3&3GY\_:(_;D_:T_91_9SO?VT/BG\$?`&M^`=,T:UU37M"\*^,KG^U]
M*MI)HD<P32VQM]5(20N`/LH)4*I?=NKZM\%>++#QUX4TSQCI5M<Q6NK:=!>V
ML=Y;M#,L<L:NHD1AE'`894\@Y!Y%*G0ITW=`VV2>*O"VA>--!N_"_B?1[;4-
M.U"V:WO;*[B#QS1,,,C*>""*^:K;_@ESX4^'WB&?6/V:OV@O'WPTM;R,"^TG
M0-46>WE<;?G`N`Y!^4=23Z$#BOI+QBOBJ3P[>0^"+C3XM7:V<:=+JL#RVRS$
M?*9$C969,]0&!/3(KXY^`?[:G[;'QG_;P^,?[%=W9?"NQ/P8MO#EUJ.OQ:5J
M3_VM%JELUP4CB-U^X>-4*Y9G#$YP`"*)T*527-):@FT=K?\`_!/7XR^)-%DT
M#QG_`,%"?BG?6ER"EY;PR6\*RQ[LA<A=R\8!(/)SP`<5ZQ^SE^R-\"_V6-"D
MT7X0>#(K*6XB1+_5+AS->7FWH996Y(R20HPHSP!7IBMN&<=Z\\_:Y^,>J?L[
M_LL_$?X_:'H]OJ-YX(\"ZMKUKI]V[+%<R6EG+<+&Y7D*QC`)'(!-*.'I0=T@
M;;/1,`=!7Q[X=_X)*VG@7XD:U\4OAC^UAX[\,:IKEW<RW<ND1VR?)-*96BY0
M[E#'C.3P#UYK:_8N_:O_`&BOVAY?#>I?$2VT:PMM3\.1ZIJEA:?";Q1IJQ&2
M%66*'4=26.WEVO(G.T%U#%5&,CZH!R,TZM"E6:<UML";6Q\T_P##"GQO_P"D
MC'Q:_P"^[/\`^-U[[X%\,7W@WPIIWAB]\1WVL2V%E'!+JNIS;[B[=5PTLA_O
M,<DXX&<#`KRO]O;]M;PK^PI\%K;XK^)?"=UK,VJ^(;'0M&M5G^RV@OKN98HG
MO;UU,5A;`G+SR<#`"AW95/0_!S4/VH]5UBXU7XY1_#RPTNX20Z;I'A"XO;V>
M'YQL9[V=84F!0$G;;QX+`9(4EG"C"F_=$>F5\^_!7_@G_P"#O@K^U#XH_:CT
MKQ_JU]J/B@WYN=*NX(5MX/M5PD[;2HW':4"C)Z'FOH*O`OV]_P!LK4?V,M.^
M%VN6O@.Z\06OCGXLZ;X3U2#3=/N;R\MK:YM[J5KBWM[96DGD0VZ_(%)VEC@X
MISI0J-.2O;5#3:/?:*^.O'/_``5+6#_@H-\!?V-_A[\+M8;2OBS;^)9-;UKQ
M=X0UC1+BP;3;`7,0M4OK>%;@.25?&[9QG&X9^Q:T$<)^TE\"]+_:0^"VN?!7
M6]=N=-M-=ABCFOK.-6EB"31R@J'RIR8P.?6J'[*7[..B_LI_!O3_`(,>'/$E
MYJ]I87-S,E]J"(LKF:9I2"$`7`+8&!VKTJBLO8P]IS]=@"O)OVPOV4O#_P"V
M)\*XOA3XG\57^C6T.KPZ@MYIL4;R%HTD4)B0$8/F'/?BO6:^:OV4/VX/%O[0
M7[<7[2/[*.M>!]-T[3O@AJOAZTTG5;2>1I]274=/:Z=IE;Y4*,NT;>HZU<X1
MJ1<9;,#U7]F'X`Z-^S'\%='^"V@>(+O5+31S.8KZ^1%ED\V>28[@@`&"Y''8
M5V/B+PUH?BS0[OPUXETJWOM/OK=X+RSNX1)%-$PPR,IX(([5?KY?_;G_`&U_
MCI^S5\=_A=\*_@G^S_;_`!"_X2[2?$>K:[I$&I&WU22STJ.S=XM.##RI;IA=
M%ECE9%?RM@=68&DJ<5%16R`J7/\`P2K^'WA'Q[<>/?V</C7XU^&$EZC"\T_P
MS?JUNY)_A64':HYPN2!GY=M:;?\`!/\`^(.N_P#$N\?_`+=_Q>U;2VYFL8=6
MALV=ARI$L,8=<'!P.O3IFN8_9K_X*E:/^U;^VYI/[/7PF\`2MX(U/X+3^,?^
M$KU..:WO8-5AU2"RN-&FM70?9Y[<2JTR,2RF6/@*P+?7]9+"T%HD5S2.<^&/
MP]3X7>!--\!6?B;5]7ATRW\F+4-?OC<W<JY)'F2D`N0#@$C.`*\C^.'[`OAO
MXV>-]3^(TGQZ^)GA_5]1M8X(SX?\5-;VMJL:D(%@5<%02S$$\L['O4G[;G[<
MFG?L@W_PT\'VG@4:YXB^*_CR#PKX634-2:PTRWN70R-)>7@AF,"[%(15C=Y'
M(4+C<R]W\$[O]HF6QNKO]H6X\$1W4XC>QL/!B7;I:`EMZ//<L#<8^4!UBBR0
M24&0!<J-.<>5K02;6QXZ?V$OVBTU163_`(*.?$[[`+7'E^7:F<S;N#O*[=FW
M(V[=V>=V.*V/@?\`\$T_@/\`!_XAM\9->O=8\:^,I)EN9/$'BVY2X=;H,2;F
M-`H"2=!NYVA1MVU]%4R6=(6568`MT!;&:A86@FG;8?-(>!@`>E%%%=!($`]1
M7%_'?X"_#;]HWX=7WPP^*6@)?:9>KD,#MEMI1]R:)^J2*>01[@@@D'M**F48
MSBXR5TP/S`USX$?MT?\`!+WX@:GXT_9W2\\7?#J>X,]S9B(W".FT?\?=O'AX
MY%'R^?'A3@%N/DKW'X(?\%J/V:/'6E6UO\7+;4/!FJLQ2Y$MJ]W9@A22ZRQ*
M6"G;@!D!!8#GK7V48%;[Q[Y%>+?%?_@GC^Q]\9RUQXP^"FD073S&22^T2,Z?
M-(Q;<Q=K<IO+$G);).37G?5<10E>A+3^5[+T\BW.,MS8C_;=_8\D0./VF_`P
MW`$`^)[8=?J]87Q#_P""C?[%GPWT;^VM2_:`T'4,Y$=KH-S]OFD([!(-V/\`
M@6`>U>0R?\$,_P!DYW++XZ\=*I8E5_M2U.T9Z<VWX5L>"?\`@BU^QKX2U+^T
MM9A\3>(@'1H[;6-9"Q(5;)XMTBW`]"&)&.W--SS-Z*$5\V*T#Q_XS_\`!83X
MG?%OQ3'\(?V'?A3>W-_?S>3:ZQJ5D)KJ4E@H>&VR4C7D'S)B0`<LJUUG[$O_
M``2PU?1O&"?M'_MC:FVN^,)KU[Z+0KF<7$,-PS!EN+F3D33`@D*,HOR]2HQ]
M=?"C]G[X,?`W3FTSX1_#71_#\;IME;3K)4DE&21OD^^^"3C<3C-=A''LSSG-
M.G@I3DIUY\S[=$'-I9!&&"C=UQS3J**]$D\S^-/[(G[/G[0GBS0O'7Q8^&\.
MH:[X7CN8_#VOVM_<65_I\=PH6=(KFVDCE1'``90V#CI6[\+/@-\'?@I:W=I\
M)OA?H'AM;Z42WS:)I,5NUW)@#S)F10TKD`99RS'')KKZ*`"N0\<_`GX2?$;X
M@^$OBMXS^'^F:EXD\"7=U<^$-:NK?-QI4ES`UO.87&"OF1,58<@\$C(!'7T4
M`-CW;`&&#5+Q1X7\/>-?#M]X1\6Z'9:GI6IV<MIJ>F:C:I/;W<$BE)(I(W!5
MT925*D$$$@U?HH`\CTW]@[]CC1;ZUO\`3?V9?!`-A<1SZ7!)X=@>#394<.'M
M864QVK%PK,T2H6959BS`$>N8`Z"BB@`(!ZBN0\-_`?X1>$OBQXC^.?AKX>:7
M8>+?%UE96GB;7K6WV7&IQ6@<6RS$</Y8D<*2,X(&<``=?10`5C?$/P#X2^*G
M@36?AIX^T2'4]"\0:7<:=K.FW`)CN[6>-HY8FP0=K(S*?8ULT4`?/OP-_P""
M6O[!7[-7Q&T[XM?`S]FS1_#GB'28Y4T[4[.\NF>W62)HG"K)*RX,;,N,<`\8
MKZ"HHH`RO&O@CPC\1_"U]X'\?>&-/UK1M3MFM]2TG5K)+BVNHFX9)(I`5=3Z
M,"*X7X5_L=?LS_!'Q.WBWX4?!'P_H5]OG:VFL;(`6`F_UR6JG*VB2'YGCA"(
M[99@3S7I]%`!7,_$'X1_#OXJW?A^[^(?A.UU27PMXABUSPZ]R"38ZA%')''<
MI@CYU2:0#.1\YXKIJ*`./\4?`;X1^,OBIX:^.'B?X?:7?^+?!]K>V_A;7[JW
MWW&EQWBQK<B$DX0R+$BD@9P",X)!Z]`0H!'.*6B@`HHHH`*Y#P1\"/A)\-/'
M?BSXF^`?A]I>E^(/'=_;WGC#6+2V"W&JS00K!"TSG);9$H55X`&<#+$GKZ*`
M"N8\1?"#X=>*OB1X?^+NN^%+:Z\2>%+6]M_#NKR9\VQBO!&MRB<XQ((8PV0?
MN#&*Z>B@#S[1OV7?@)H/[0&H?M3Z1\*]'M?B%JVAC1]4\5VUMLNKRR#QL(I2
M#A^8HOF(W8B1<X4`>@T44`<]\3?A3\-?C+X6?P-\6/A]HGB?19IHY9M)\0:5
M#>6SNC!D<QS*REE8`@XR#R,5R?PG_9`_9P^!FN/XF^$OP:T+0[]A.L-S9VOS
M6L4TGF2P6^XG[-`S_.88MD9<EMN22?3:*`"N4\?_``4^%?Q2\2^'/%WQ`^'F
MD:UJ7A&_:^\-7NIV23/IUPP`,L.X?(^%7GL54CE01U=%`!1110!'1110`444
M5+W0!1115`%%%%);`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
J****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
